Routine Bone Marrow Biopsy Does Not Provide Prognostic, Diagnostic Value Over PET/CT in Most With DLBCL

Share this content:
Routine bone marrow biopsy did not contribute relevant diagnostic or prognostic value over positron emission tomography/computed tomography alone.
Routine bone marrow biopsy did not contribute relevant diagnostic or prognostic value over positron emission tomography/computed tomography alone.

Routine bone marrow biopsy (BMB) did not contribute relevant diagnostic or prognostic value over positron emission tomography (PET)/computed tomography (CT) alone in most patients with diffuse large B-cell lymphoma (DLBCL), according to a study published in the Annals of Oncology.1

Investigators sought to determine if routine bone marrow biopsy added diagnostic and prognostic value in patients with diffuse large B-cell lymphoma undergoing PET/CT staging.

Investigators retrospectively identified 530 patients with newly diagnosed DLBCL who underwent staging PET/CT and BMB. Original PET/CT pathology reports were reviewed to determine Ann Arbor stage and outcomes, with and without the contribution of BMB.

A total of 28% of patients had focal bone marrow lesions on PET/CT; 16% had positive BMB. A total of 36% of patients with positive PET/CT had a positive BMB (39 DLBCL and 13 indolent non-Hodgkin lymphoma [iNHL] and 9% with negative PET/CT had positive BMB [12 DLBCL; 23 iNHL).

For 6% of stage 1/2 patients, BMB upstaged them to stage 4, even though that was only true for 3 patients with DLBLC in the BMB. PET/CT identified bone marrow involvement by BMB with a sensitivity of 60%, specificity of 79%, positive predictive value 36%, and negative predictive value 91%.

RELATED: Novel Dual HDAC/PI3K Inhibitor Assessed in Lymphoma, Myeloma

In univariate and multivariate analyses, concordant histological involvement of the bone marrow by DLBCL was associated with worse overall survival and progression-free survival than discordant or no involvement.

“In patients with DLBCL, staging PET/CT can miss BM involvement with concordant DLBCL (less common) or discordant iNHL (more common),” the authors concluded.

Reference

  1. Alzahrani M, El-Galaly TC, Hutchings M, et al. The value of routing bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study [published online ahead of print March 21, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw137.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters